Abstract: Assay methods and kits for detecting and quantifying anti-Epstein-Barr Virus ("EBV") antibodies in a sample. The methods comprise contacting samples with a free or immobilized synthetic antigenic EBV polypeptide that is recognized by human antibodies and detecting or quantifying immunocomplex formation. The polypeptides described are the carboxy-terminated one-third of the EBV Nuclear Antigen encoded by the EBV Bam H1 K-fragment (plasmid pNAK28), a 46-55 kDa EBV Early Antigen encoded by the 4340 base pair Bcl 1 to Bam H1 restriction fragment within the EBV Bam H1 M-fragment (plasmid pEAD), and an EBV viral capsid antigen. Bacterially synthesized fusion proteins are recognized by human anti-EBV antibodies. The assay method is diagnostic for infectious mononucleosis, chronic mononucleosis, Burkett's lymphoma and monopharyngeal carcinoma.

Abstract: Bacterially synthesized polypeptides that are recognized by antibodies produced in EBV-infected humans are disclosed. Plasmids containing DNA sequences encoding portions of the EBNA and EBEA-D antigens are also disclosed, as are methods for expressing these DNA sequences in bacteria. The DNA sequence encoding the EBNA-1-related fusion polypeptide is found in a Bam H1 K-restriction fragment, while that encoding the EBEA-D-related fusion polypeptide is found in a Bam H1 M-restriction fragment.